Results 81 to 90 of about 152,115 (284)

Association of HAMP Expression and CD8+ T‐Cell Infiltration With Atezolizumab–Bevacizumab Response in Hepatocellular Carcinoma

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
In hepatocellular carcinoma treated with atezolizumab–bevacizumab, responders showed RNA‐seq enrichment of immune and chemokine pathways with higher HAMP expression. In resected specimens, immunohistochemistry confirmed increased intratumoral CD8+ T‐cell density and hepcidin (HAMP), supporting HAMP plus CD8 as components of a composite predictor of ...
Shun Nakamura   +9 more
wiley   +1 more source

Primary Tumor Resection in Patients With Unresectable Metastatic Colorectal Cancer: A Systematic Review and Meta‐Analysis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This systematic review and meta‐analysis evaluated the role of primary tumor resection (PTR) in asymptomatic patients with unresectable metastatic colorectal cancer. Across 17 eligible studies including 9317 patients, PTR did not improve overall or progression‐free survival compared with chemotherapy alone.
Junpei Takashima   +3 more
wiley   +1 more source

Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data

open access: yesTumor Biology, 2017
To evaluate the association between severe pulmonary embolism events and bevacizumab, we conducted the first meta-analysis evaluating the incidence and risk of pulmonary embolism associated with bevacizumab-based therapy.
Meidan Liu   +8 more
doaj   +1 more source

Perfusion imaging of colorectal liver metastases treated with bevacizumab and stereotactic body radiotherapy

open access: yesPhysics and Imaging in Radiation Oncology, 2018
Stereotactic body radiotherapy (SBRT) and bevacizumab are used in the treatment of colorectal liver metastases. This study prospectively evaluated changes in perfusion of liver metastases in seven patients treated with both bevacizumab and SBRT ...
Jay S. Detsky   +6 more
doaj   +1 more source

Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. [PDF]

open access: yes, 2013
PurposePatients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease. methods: Given the overall poor prognosis in this population and the availability of novel targeted therapies, we ...
Falchook, Gerald S   +14 more
core   +2 more sources

Surgical Outcomes and Recurrence Management in Borderline Resectable Hepatocellular Carcinoma: Implications for Multidisciplinary Strategies

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Multivariate analysis identified that up‐to‐7 out (p < 0.001), lymph node metastasis (p < 0.001), and non‐anatomical resection (p = 0.02) were independent predictors of cancer recurrence, while older age (p = 0.01), Child‐Pugh B (p < 0.001), up‐to‐7 out (p = 0.01), macrovascular invasion (p = 0.01), and lymph node metastasis (p < 0.001) were ...
Koichiro Haruki   +9 more
wiley   +1 more source

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

open access: yes, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim   +3 more
core   +2 more sources

Relationship Between the Product of Pre‐Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown.
Takayoshi Sasaki   +9 more
wiley   +1 more source

Bevacizumab radioimmunotherapy (RIT) with accelerated blood clearance using the avidin chase [PDF]

open access: yes, 2018
学位記番号 ...
RYAN, YUDISTIRO   +1 more
core  

Cancer therapy‐induced ototoxicity: Current challenges and emerging management strategies

open access: yesAnimal Models and Experimental Medicine, EarlyView.
This review comprehensively examines the key risk factors for cancer therapy‐induced ototoxicity, including cumulative drug dose, genetic susceptibility, and combined treatment regimens. It highlights current challenges in ototoxicity monitoring, such as insufficient timeliness and limited clinical adoption, and advocates for standardized auditory ...
Yuqi Huang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy